Navigation Links
ISTA Pharmaceuticals Highlights Clinical Data from REMURA™ Phase 2 Study Presented at the 6th International Conference on the Tear Film & Ocular Surface
Date:9/27/2010

IRVINE, Calif., Sept. 27 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today highlighted results from the Company's REMURA™ (bromfenac ophthalmic solution for dry eye) Phase 2 clinical study.  The study achieved statistical significance in the primary endpoint of the objective sign of conjunctival staining (p<0.001) as compared to baseline. The study also achieved statistical significance on the objective sign of corneal staining (p<0.01) as compared to baseline. In addition, patients achieved statistically significant improvements in subjective symptoms measured by the Ocular Surface Disease Index* (OSDI) (p<0.001) and in patients' most bothersome ocular symptoms.  Patients treated with REMURA maintained the improvements in the signs and symptoms of dry eye disease for 10 days after discontinuing treatment, which was evaluated at the time of the follow up visit.  Adverse events were uncommon, and there were no serious ocular or systemic adverse events.

These results were presented in poster sessions at the 6th International Conference on the Tear Film & Ocular Surface in Florence, Italy, in poster presentations titled "Bromfenac Ophthalmic Solution for Treating the Signs of Dry Eye Disease" and "Alleviation of Dry Eye Disease Symptoms with Bromfenac Ophthalmic Solution."

ISTA's REMURA Phase 2 study enrolled 38 patients who exhibited signs and symptoms consistent with moderate dry eye disease. The study was designed to investigate the effects of REMURA compared to baseline on the objective signs of conjunctival staining (Lissamine Green test) and corneal staining (Fluorescein test), as well as subjective symptoms (OSDI and patients' most bothersome ocular symptoms), when administered under normal environmental conditions.  All patients received REMURA in both eyes, twice daily, for 42 days. Patient baseline
'/>"/>

SOURCE ISTA Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Jiangbo Pharmaceuticals Announces Conference Call to Discuss Results for Fourth Quarter Fiscal 2010
2. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
3. TOPICA Pharmaceuticals Announces Sublicensing Agreement for Tinea Indication
4. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
5. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
6. Edimer Pharmaceuticals and CMC Biologics Announce Agreement to Manufacture EDI200 Recombinant Protein
7. Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
8. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare and Baird Global Healthcare Conferences
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402.
11. NanoSmart™ Pharmaceuticals, Inc. Receives Patent Allowance for Tumor Targeting Platform Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... -- Lisa Kulik saw fireworks for the first time in ... a groundbreaking retinal implant co-invented by Mark Humayun ... University of Southern California (USC) Eye Institute. ... resident who has retinitis pigmentosa, a degenerative disease ... 2, she became the first person west of the ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com has ... The Graphene Opportunity - A Rational View ... The New Nanotech? A similar amount of ... applications ranging from microelectronics to water treatment, but ... the availability of the Graphene Opportunity Report, authored ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... 2014 After the boom of the ... next beverage craze is going to be the stress ... can use Stress Relief energy pattern which can be ... of a beverage, including minerals, herbs and liquids. Stress ... that power into rapid recovery and helping to adapt ...
Breaking Biology Technology:USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 2USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 3USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 4USC Eye Institute ophthalmologists implant first FDA-approved Argus II retinal prosthesis in western United States 5The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
... 28 N30 Pharma (N30), a,biopharmaceutical company focused ... regulate nitric oxide bioavailability,announced today that it has ... N30 will use proceeds from this financing ... expand its discovery and preclinical,research in the area ...
... Be Webcast Live On Company,s Website -, TUSTIN, ... ), a clinical stage biopharmaceutical,company developing monoclonal antibodies for ... that senior management will,present at the BIO Investor Forum ... (6:45 pm EDT). The conference will be held at ...
... ITMN ) announced today that it will release ... at 4:00 p.m. Eastern time.,A live conference call and ... time that same day., To access the live ... To access the,webcast, please log on to the company,s ...
Cached Biology Technology:N30 Pharma Announces Financing, Expansion of Board 2Peregrine Pharmaceuticals to Present at BIO Investor Forum 2008 2InterMune to Release Third Quarter 2008 Financial Results on November 6 2
(Date:8/27/2014)... (June, 2014) Outstanding basic research, a growing ... dedication to patient care have earned the Herbert ... Medical Center (CUMC) and NewYork-Presbyterian Hospital an $18 ... National Cancer Institute (NCI). The grant renews the ... Comprehensive Cancer Centers in New York City and ...
(Date:8/27/2014)... factors thought to be associated with outcomes after ... age of the patient, mechanism of injury, nerve ... method, operation technique, and repair materials. However, despite ... peripheral nerve injuries, there is no agreement regarding ... the dose-effect relationship of the predictors has not ...
(Date:8/27/2014)... research finds , Gamblers show the same tendencies ... has shown. , Researchers, led by Dr Elliot Ludvig ... tests that found that both human gamblers and pigeons ... low-value rewards. , Published in Biology Letters , ... important role that memories of previous biggest wins and ...
Breaking Biology News(10 mins):Herbert Irving Comprehensive Cancer Center awarded $18 million grant 2Herbert Irving Comprehensive Cancer Center awarded $18 million grant 3Herbert Irving Comprehensive Cancer Center awarded $18 million grant 4Gamblers are greedy bird-brains, University of Warwick research finds 2
... the body's motor nerve cells grow along proper paths ... inhibiting spinal-cord neurons from regenerating after injury, researchers at ... the researchers found that a component of myelin ?a ... in adult vertebrates ?chemically blocks the ability of nerve ...
... for the first time that bacteria, in addition to ... sparkling wine known as Cava. They report their findings ... Society for Microbiology. , "Bacteria found in Cava samples ... in terms of aroma, flavor, bubble size and bubble ...
... hanging basket style device is at the heart of a plan ... sex drive of a major pest of fruit ... that very same pest. The device allows growers to selectively ... killing other beneficial insects. , The researchers at Warwick HRI, the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3After the yeast is gone bacteria continue to develop flavor of sparkling wine 2Hanging baskets of sex and death help fruit growers 2